The role of HER2 in angiogenesis

https://doi.org/10.1016/S0093-7754(01)90279-9Get rights and content

Abstract

Recent studies have established that growth factors and their receptors play an essential role in regulating the proliferation of epithelial cells. Abnormalities in the expression, structure, or activity of their proto-oncogene products contribute to the development and maintenance of the malignant phenotype. For example, c-erbB2 encodes the human epidermal growth factor receptor 2 (HER2), which is overexpressed or amplified or both in several human malignancies including breast, ovarian, and colon cancers. Tumor cells must use the process of vascularization (angiogenesis) for productive growth and metastasis. Overexpression of HER2 in human tumor cells is closely associated with increased angiogenesis and expression of vascular endothelial growth factor (VEGF). Indeed, when the VEGF pathway is inhibited, tumor growth is suppressed. The anti-HER2 blocking antibody trastuzumab has been shown to inhibit tumor cell growth and VEGF expression. Cancer cell invasiveness can be promoted, even in the absence of HER2 overexpression, by transregulation of HER2 by heregulins that bind to HER3 and HER4. Accordingly, heregulin β1 regulates the expression and secretion of VEGF in breast cancer cells, and trastuzumab inhibits heregulin-mediated angiogenesis both in vitro and in vivo. Thus, potential upregulation of VEGF in cancer epithelial cells likely supports angiogenesis, sustaining and promoting survival and metastasis of tumor cells.

References (46)

  • PO Hackel et al.

    Epidermal growth factor receptors: Critical mediators of multiple receptor pathways

    Curr Opin Cell Biol

    (1999)
  • K Anan et al.

    Assessment of c-erbB2 and vascular endothelial growth factor mRNA expression in fine-needle aspirates from early breast carcinomas: Preoperative determination of malignant potential

    Eur J Surg Oncol

    (1998)
  • R Bagheri-Yarmand et al.

    Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-b1-mediated angiogenesis

    J Biol Chem

    (2000)
  • S Burden et al.

    Neuregulins and their receptors: A versatile signaling module in organogenesis and oncogenesis

    Neuron

    (1997)
  • IJ Fidler

    Modulation of the organ microenvironment for treatment of cancer metastasis

    J Natl Cancer Inst

    (1995)
  • L Holmgren et al.

    Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

    Nat Med

    (1995)
  • HP Dvorak et al.

    Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis

    Am J Pathol

    (1995)
  • J Rak et al.

    Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis

    Cancer Res

    (1995)
  • D Shweiki et al.

    Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

    Nature

    (1992)
  • BH Jiang et al.

    Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells

  • AM Petit et al.

    Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors

    Am J Pathol

    (1997)
  • D Graus-Porta et al.

    ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

    EMBO J

    (1997)
  • R Pinkas-Kramarski et al.

    Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions

    EMBO J

    (1996)
  • Cited by (173)

    • Optimizing combination therapy in a murine model of HER2+ breast cancer

      2022, Computer Methods in Applied Mechanics and Engineering
    View all citing articles on Scopus

    Supported by the National Institutes of Health grants CA65746 and CA80066 and the Breast and Ovarian Research Programs of The University of Texas M. D. Anderson Cancer Center (RK).

    View full text